• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Baillie Gifford Global Discovery Fund B Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Baillie Gifford & Co Limited.
Fund Summary The Sub-fund aims to outperform (after deduction of costs) the S&P Global Small Cap Index, as stated in Sterling, by at least 2% per annum over rolling five-year periods. The Sub-fund will invest at least 90% in shares of companies. The Sub-fund will be actively managed and will invest in shares of companies in any country and in any sector which typically at the time of initial purchase have a market capitalisation of US$5 billion or less and that the ACD considers will offer excellent future growth prospects. To the extent that the Sub-fund is not fully invested in such shares, the Sub-fund may also invest in other transferable securities of companies anywhere in the world, money market instruments, deposits and cash. The Sub-fund may not invest in or otherwise use derivatives.
SEDOL code 0605933
ISIN GB0006059330
Fund code BFGDA
Managers Douglas Brodie, Svetlana Viteva, Luke Ward
Manager Tenure 9 years
Morningstar Category Global Small-Cap Equity
IMA Sector Global
Fund Size £908 million
Fund Type OEIC
Management Style Active
Ongoing Charge Figure (OCF) 0.78%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £20.3100
Buy Price £20.3100
Price Change +0.0986%
Price Date 22nd May 2020
Yield Currently unavailable
Dividend Frequency Yearly
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 11th November 2013
Fund Status OPEN
Douglas graduated BSc in Molecular Biology & Biochemistry from Durham University in 1997 and with a DPhil in Molecular Immunology from the University of Oxford in 2001. He joined Baillie Gifford in 2001 and is Head of the Global Discovery Team. Douglas became a Partner in 2015 is a CFA Charterholder.

3-year Mean Monthly Return: 1.803%

Annual Returns 2019 2018 2017 2016 2015 2014 2013 2012
Fund Performance -0.91% +19.91% +25.34% +24.33% -1.83% +16.79% +32.00% +25.22%
Benchmark Performance
(Global Small-Cap Equity)
-16.04% +2.28% +4.60% +30.70% -0.31%
Time Period Cumulative Benchmark Performance
(Global Small-Cap Equity)
Fund Compared to Benchmark
1 day 0.10% -7.01% +7.11%
1 week 4.21% +12.34% -8.14%
1 month 18.84% -8.87% +27.71%
3 months 10.08% -5.79% +15.87%
6 months 25.45% -3.34% +28.79%
1 year 26.94% +2.52% +24.42%
3 years 23.36% +7.09% +16.26%
5 years 18.72% +8.17% +10.55%
10 years Currently unavailable Currently unavailable Currently unavailable
YTD 25.29% +5.01% +20.28%
Since inception 17.98% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Alnylam Pharmaceuticals Inc USA 5.93%
Zillow Group Inc C USA 4.20%
MarketAxess Holdings Inc USA 4.10%
Teladoc Health Inc USA 3.87%
Ocado Group PLC GBR 3.79%
Tesla Inc USA 3.70%
Chegg Inc USA 3.46%
LendingTree Inc USA 3.32%
NovoCure Ltd USA 2.78%
Genmab A/S DNK 2.25%
Dividend Date Per share amount Reinvestment Price
1st May 2013 0.0009 £5.5410
1st May 2012 0.0365 £4.3660
3rd May 2011 0.1073 £4.5460
4th May 2010 0.0530 £3.6750